A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study).
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Telbivudine (Primary) ; Adefovir
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms EFFORT
- 01 Feb 2018 Results of retrospective analysis assessing effect of HBV subgenotype on treatment response using patient data from NCT00962533, NCT00057265 and NCT00131742 trials published in the Hepatology Research
- 02 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.(Parent trial: NCT00962533).
- 10 Feb 2012 An extension study was initiated in August 2011 (ClinicalTrials.gov, NCT01529255).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History